North Carolina is currently home to 2737 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Winston-Salem, Charlotte and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Phase 3, Multi-Center Study Evaluating PL9643 in Patients With Dry Eye
NCT05201170
Recruiting
This is a multi-center, double-masked, randomized, vehicle-controlled study testing PL9643, an opthalmic solution to determine if safe and efficacious for dry eye patients. After a 2-week run-in period, patients will be randomized equally to the PL9643 opthalmic solution or vehicle opthalmic solution administered bilaterally three times a day for 12 weeks. A Data Monitoring Committee will be engaged to review interim data.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/08/2022
Locations: Palatin Clinical Site #8, Mint Hill, North Carolina
Conditions: Dry Eye, Dry Eye Syndromes
Register for Updates
Longitudinal Performance of Epi proColon
NCT03218423
Recruiting
This study will evaluate longitudinal performance of Epi proColon with respect to test positivity, longitudinal adherence to Epi proColon screening, adherence to follow-up colonoscopy and diagnostic yield, as well as assay failure rates.
Gender:
All
Ages:
Between 50 years and 74 years
Trial Updated:
10/29/2021
Locations: Duke University, Durham, North Carolina
Conditions: Colorectal Cancer, Colorectal Neoplasms
Register for Updates
Antiretroviral Pregnancy Registry (APR)-Risk of Birth Defects
NCT01137981
Recruiting
The APR began as the 'Zidovudine in pregnancy Registry' in January 1989 and became the 'Antiretroviral Pregnancy Registry' in January, 1993. The purpose of the APR is to detect any major teratogenic effects involving any of the Registry drugs when administered to pregnant HIV positive women. The Registry is intended to provide an early signal of teratogenicity associated with prenatal use of the antiretroviral drugs. The Registry collects data on prenatal exposures to antiretroviral drugs, poten... Read More
Gender:
Female
Ages:
All
Trial Updated:
10/04/2021
Locations: GSK Investigational Site, Wilmington, North Carolina
Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Register for Updates
Prospective, Randomized, Controlled Agreement and Reproducibility Clinical Study
NCT05026658
Recruiting
Visual acuity is the relative ability of the eye to resolve detail that is usually expressed as the reciprocal of the minimum angular separation in minutes of two lines just resolvable as separate and that forms in the average human eye an angle of one minute. Visibly Inc. has developed a method for determining a patient's visual acuity electronically via a web-based software system that can be self-administered wherever convenient. This method provides an efficient alternative for people to ha... Read More
Gender:
All
Ages:
Between 22 years and 40 years
Trial Updated:
09/17/2021
Locations: Core, Inc, Shelby, North Carolina
Conditions: Digital Acuity Product
Register for Updates
Continuous Monitoring and Control of Hypoglycemia
NCT03340831
Recruiting
Evaluate safety of non-adjunctive CGM use in CGM naive participants.
Gender:
All
Ages:
2 years and above
Trial Updated:
09/17/2021
Locations: Mountain Diabetes and Endocrine Center, Asheville, North Carolina
Conditions: Diabetes
Register for Updates
Myeloma-Developing Regimens Using Genomics (MyDRUG)
NCT03732703
Recruiting
The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment arms. These arms have treatments specifically directed to the mutated genes. Patients that do not have a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/09/2021
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Relapsed Refractory Multiple Myeloma
Register for Updates
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
NCT03509961
Recruiting
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be eligible to receive a non-TBI conditioning regime... Read More
Gender:
All
Ages:
Between 1 year and 25 years
Trial Updated:
08/20/2021
Locations: Atrium Health - Levine Cancer Center, Charlotte, North Carolina
Conditions: B-cell Acute Lymphoblastic Leukemia
Register for Updates
Prospective US Radiofrequency SUI Trial
NCT04720352
Recruiting
PURSUIT: Prospective US Radiofrequency SUI Trial (VI-17-06) is a prospective, randomized, sham controlled, double blind study in premenopausal women with stress urinary incontinence. The study will be conducted in 390 subjects, randomized 2:1 with active or sham treatment. Study duration is 12 months post treatment. The primary objective is to evaluate the efficacy of the Viveve treatment, SUI protocol, in improving mild to moderate stress urinary incontinence (SUI), assessed using the 1-hour Pa... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
07/19/2021
Locations: Unified Women's Health Care of Raleigh, Raleigh, North Carolina
Conditions: Urinary Incontinence, Stress
Register for Updates
Building Resiliency and Vital Equity (BRAVE) Project: Understanding Native Americans' Perceptions/Beliefs About COVID-19 Testing and Vaccination Study
NCT04964154
Recruiting
The Building Resilience and Vital Equity (BRAVE) project seeks to partner with American Indian tribal communities in North Carolina to establish COVID-19 services and resources for American Indian communities. The goal of this study is to 1) understand the barriers and social implications of COVID19 testing and vaccination among American Indians by designing and implementing culturally sensitive survey tools and intervention materials; 2) Implement BRAVE outreach and testing interventions to inc... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/13/2021
Locations: Lumbee Tribe Tribal Housing Complex, Pembroke, North Carolina
Conditions: Covid19 Virus Infection
Register for Updates
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
NCT04916210
Recruiting
The overall goal of the DISCOVERY study is to better understand what factors contribute to changes in cognitive (i.e., thinking and memory) abilities in patients who experienced a stroke. The purpose of the study is to help doctors identify patients at risk for dementia (decline in memory, thinking and other mental abilities that significantly affects daily functioning) after their stroke so that future treatments may be developed to improve outcomes in stroke patients. For this study, a "stroke... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2021
Locations: Wake Forest Baptist Health, Winston-Salem, North Carolina
Conditions: Ischemic Stroke, Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Dementia, Vascular, Mild Cognitive Impairment, Vascular Cognitive Impairment
Register for Updates
Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment
NCT04868253
Recruiting
This open-label study will evaluate EMB-001, comprised of metyrapone, a cortisol synthesis inhibitor marketed as a diagnostic drug for testing hypothalamic-pituitary-adrenal (HPA) axis function, combined with oxazepam, an anxiolytic and sedative/hypnotic benzodiazepine, to help smokers abstain from smoking during a 12-week trial period.
Gender:
All
Ages:
Between 21 years and 65 years
Trial Updated:
05/26/2021
Locations: Rose Research Center, Raleigh, North Carolina
Conditions: Smoking Cessation, Tobacco Use Disorder
Register for Updates
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
NCT03250338
Recruiting
This is a randomized, multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy of crenolanib administered following salvage chemotherapy, consolidation chemotherapy, post bone marrow transplantation and as maintenance in relapsed/refractory AML subjects with FLT3 activating mutation.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/28/2021
Locations: Wake Forest Baptist Medical Center, Winston-Salem, North Carolina
Conditions: Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Register for Updates